Contact us

Antibody
Conjugation

Start your project

Any payload, any format

Antibody Conjugate fitting your science

We specialize in tailored, high-performance immunoconjugate production, including ADCs, DACs, and AOCs. Technology-agnostic by design, we work across all conjugation formats and platforms. From feasibility to preclinical supply, we support your program with flexible formats, multiple conjugation technologies, and comprehensive analytical packages.

Custom reliable Antibody Conjugate

Any antibody format and multiple conjugation strategies. We deliver high-quality, QC-controlled antibody conjugates

Derisk your project

Expert guidance to accelerate antibody conjugate development from concept to scale

Full Service Approach

Achieve program success through our end-to-end integrated platform

Tailored Antibody Conjugates without Compromise

More than 220 Ab conjugates produced

Proven track record across diverse antibody formats, payloads, and conjugation chemistries.

From milligram to gram-scale

Supporting discovery, preclinical, and scale-up phases with flexible production capabilities.

Custom fully Integrated Project Solutions

We adapt to your needs and built antibody conjugates to your specifications.

Quality assurance

ISO 9001 certification guarantees the quality of our services.

We design and perform custom antibody conjugation tailored to your application. Any antibody format, IgGs, scFvs, bispecifics, VHHs, can be linked to diverse payloads, including topoisomerase inhibitors, DNA-damaging agents, microtubule inhibitors, PROTACs, dyes, or oligonucleotides… Technologies: site-specific, native cysteine (DAR 4–8), enzymatic (BTG), click chemistry.
Our purification workflows ensure high-quality ADCs compatible with both discovery and preclinical development. Using advanced techniques such as SEC and TFF, we deliver consistent DAR homogeneity, residual toxin clearance, optimal stability, and reproducibility, providing purified ADCs ready for downstream assays, in vivo studies, or preclinical applications.
Each ADC undergoes comprehensive quality control to ensure the highest standards of safety, reproducibility, and compliance. Our panel includes:
  • Concentration determination
  • DAR determination
  • Residual toxin estimation
  • Monomeric purity
  • Hydrophobicity profiling
  • Endotoxin level assessment

Our Expertise Across Multiple Conjugation Strategies

We developed a wide range of robust strategies to conjugates IgGs, scFvs, bispecifics, or VHHs to linkers and payloads, including site-specific, cysteine (DAR 4–8), enzymatic (BTG), or click chemistry.

Explore the table below for all available options.

Payload compatibility

ADC library

Our ADC Library program accelerates development from candidate antibodies, enabling early efficacy evaluation and informed decision-making.

The program includes :
•
Conjugation of multiple antibodies with a generic linker–payload, followed by purification and DAR/homogeneity characterization.
•
In vitro functional assays, including binding affinity and cytotoxicity
•
Selection of the most promising leads, then conjugation to a panel of linker–payloads with corresponding analytical and functional assessments.
•
In vitro cytotoxicity    

Purified ADC samples with defined DAR, QC reports, functional assay data, and a technical dossier summarizing conjugation and analytical results.

From concept to conjugate – Solutions as unique as your project

Let’s discuss your project
Contact an expert

Insights

Case study
Technical Note – Human CD3ε Knock-In Mouse Model: A Relevant Preclinical Tool for Bispecific T Cell Engagers

08/01/2026
Poster
A comprehensive discovery and engineering workflow for developing innovative anti-Nectin-4 antibody drug conjugates

08/01/2026
Event
At AACR2025

🧪 Heading to #AACR2025 and interested in advancing antibody discovery technologies? Join us at 𝗣𝗼𝘀𝘁𝗲𝗿 𝗟𝗕𝟬𝟬𝟯 on…

23/05/2025
Poster
Rapid Single-Cell Discovery of Tumor-Targeting Antibodies Using the Bruker Beacon® Platform for Therapeutic Development

12/05/2025
Event
AACR 2025 & our Poster

AACR 2025 – Heading to AACR Annual Meeting in Chicago ? Come meet our Chief Scientific Officer…

26/04/2025
Event
Festival of Biologics USA 2025

Festival of Biologics USA 2025 Meet Nathalie Joly our VP Business Development at Festival of Biologics USA…

16/04/2025
See more Insights